Innovative Research Award
Alesia Tietze
Department of Chemistry and Molecular Biology
Alesia Tietze is a researcher affiliated with the Department of Chemistry and Molecular Biology in Sweden, with a research profile identified in the supplied academic information as relating to medicinal chemistry in cancer. The profile is associated with 40 Scopus-indexed documents, 784 citations, and an h-index of 17. These bibliometric indicators provide a quantitative view of research visibility and scholarly impact, while the award assessment itself should be based on the complete research record and independently verified evidence. [3]
Abstract
The Innovative Research Award profile for Alesia Tietze documents a research career represented in the supplied data by an affiliation with the Department of Chemistry and Molecular Biology in Sweden and a subject area of medicinal chemistry in cancer. The associated Scopus record is reported as containing 40 documents, 784 citations, and an h-index of 17. [1] These metrics can be used as supporting indicators of scholarly activity and citation reach, but they do not independently establish the novelty, methodological quality, translational significance, or originality of individual research contributions. The researcher is also associated with an ORCID identifier, providing a persistent identifier for distinguishing the scholarly record. [2]
Keywords
Alesia Tietze; Innovative Research Award; medicinal chemistry; cancer research; chemistry and molecular biology; cancer therapeutics; molecular research; research impact; Scopus; ORCID; Genetics Awards.
Introduction
Medicinal chemistry occupies an interdisciplinary position between chemistry, molecular biology, pharmacology, and therapeutic development. Research in this area may involve the design, synthesis, characterization, optimization, and biological evaluation of compounds intended to address disease-associated molecular targets. In cancer research, medicinal chemistry can intersect with studies of molecular mechanisms, therapeutic targets, biomarkers, drug resistance, and precision-oriented treatment strategies.
Within this broad research environment, academic recognition generally requires consideration of both quantitative and qualitative evidence. Bibliometric indicators such as document counts, citation counts, and h-index values can provide useful measures of scholarly visibility, while publications, methodological contributions, collaborations, and demonstrable scientific outcomes provide additional context. The Genetics Awards program states that submitted research profiles may undergo screening, credential verification, cross-checking of submitted information, and committee review before selection. [3]
Research Profile
The supplied profile identifies Alesia Tietze with the Department of Chemistry and Molecular Biology in Sweden and assigns the subject area of medicinal chemistry in cancer. The reported Scopus information comprises 40 documents, 784 citations, and an h-index of 17. [1] Taken together, these values indicate a documented body of indexed scholarly output and citation activity.
The research profile should be interpreted in relation to the underlying publications rather than as a standalone ranking. Citation indicators can vary according to database coverage, publication type, disciplinary citation practices, author disambiguation, and the date on which the record is consulted. The ORCID identifier supplied for the researcher offers an additional mechanism for connecting scholarly outputs to a persistent researcher identity. [2]
Research Contributions
Based on the supplied subject classification, Tietze’s academic profile is situated within medicinal chemistry in cancer. This field encompasses research that connects chemical science with biological and therapeutic questions relevant to oncology. The precise contribution of an individual researcher should, however, be established from verified publications, research projects, patents, datasets, collaborations, and other primary scholarly evidence rather than inferred solely from a subject-area label.
For an award evaluation, relevant evidence may include the originality of research questions, rigor of experimental or computational methods, reproducibility, significance of findings, contribution to interdisciplinary research, and potential relevance to cancer biology or therapeutic development. The Genetics Awards program identifies research excellence and related scientific contributions among the areas considered within its award framework. [3]
Publications
The supplied Scopus record reports 40 documents associated with the researcher. [1] Because individual publication titles, journals, publication years, authorship positions, and DOI identifiers were not supplied in the source information for this profile, specific publications are not enumerated here. This avoids attributing research findings or bibliographic details that have not been independently established.
For formal award documentation, the publication record can be verified through the researcher’s Scopus author profile and persistent ORCID identifier. Where individual publications are evaluated, DOI metadata should be checked against the publisher or DOI registration record before being included in a nomination dossier.
Research Impact
The supplied bibliometric indicators provide a measurable representation of scholarly impact: 784 citations across 40 reported documents and an h-index of 17. [1] These indicators may support an assessment of sustained research visibility, but they should be interpreted alongside publication quality, contribution to the scientific literature, collaboration, methodological innovation, and the broader significance of the research.
In the context of cancer-focused medicinal chemistry, research impact may also be considered through the extent to which scientific findings contribute to understanding disease mechanisms, identifying therapeutic opportunities, improving molecular tools, or informing subsequent research. Such outcomes require evidence from the underlying scholarly record and should not be inferred solely from citation statistics.
Award Suitability
The supplied profile presents several elements relevant to consideration for an Innovative Research Award: a defined research affiliation, a subject-area focus in medicinal chemistry and cancer, an established indexed publication record, and measurable citation activity. The reported h-index of 17 and 784 citations may serve as supporting bibliometric evidence of scholarly reach. [1]
Final award suitability should remain dependent on the official evaluation process and verification of the nominee’s complete research record. The Genetics Awards program describes a process involving submission screening, verification of credentials, cross-checking of information, committee review, and subsequent selection. [3] Accordingly, the present article should be understood as an academic recognition profile based on the supplied information rather than as an independent declaration of award selection.
Conclusion
Alesia Tietze’s supplied academic profile represents a researcher associated with the Department of Chemistry and Molecular Biology in Sweden and with medicinal chemistry in cancer. The reported Scopus indicators of 40 documents, 784 citations, and an h-index of 17 provide quantitative evidence of an established scholarly record. [1] The associated ORCID identifier further supports persistent scholarly identification. [2]
For the purposes of the Innovative Research Award, these indicators constitute useful supporting evidence but should be considered together with the originality, rigor, significance, and documented outcomes of the researcher’s work. A complete assessment should rely on verified publications and other primary academic evidence in accordance with the award’s stated evaluation procedures. [3]
External Links
References
- Elsevier. (n.d.). Scopus author details: Alesia Tietze, Author ID 55193803000.
Scopus.https://www.scopus.com/authid/detail.uri?authorId=55193803000
- ORCID. (n.d.). ORCID record: Alesia Tietze, ORCID iD 0000-0002-9281-548X.
https://orcid.org/0000-0002-9281-548X
-
Targeted sortase A inhibition by novel peptidomimetic antivirulents against staphylococcal infections
https://pubmed.ncbi.nlm.nih.gov/41773879/
-
DNA Scission by Non-Histidine Amino-Terminal Cu(II) and Ni(II) Binding-Like Peptides
https://chemistry-europe.onlinelibrary.wiley.com/doi/10.1002/cbic.70397